BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART). MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004. Patients treated in the pre-HAART era (1984-1996) were compared with those belonging to the HAART era (1997-2004). RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness. Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy. Patients receiving HAART (n = 34) had a significantly better 2-year overall survival (OS) than those not receiving HAART (74% versus 30%, P <0.001). The 2-year OS of HAART-responders was 88% compared with 19% in patients without HAART-response (P = 0.0002). By multivariate analysis patients without HAART had a 5.6-fold higher risk for 3-year mortality [HR 5.6, 95% confidence interval (CI) 2.20-14.26]. Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33). CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.
BACKGROUND: The purpose of the study was to evaluate the outcome of Hodgkin's disease (HD) in patients infected with the human immunodeficiency virus (HIV) with respect to the use of highly active antiretroviral therapy (HAART). MATERIALS AND METHODS: This cohort study included patients with HIV-HD diagnosed from June 1984 to February 2004. Patients treated in the pre-HAART era (1984-1996) were compared with those belonging to the HAART era (1997-2004). RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness. Fifty-nine of 66 patients (89.4%) underwent curative intended chemotherapy. Patients receiving HAART (n = 34) had a significantly better 2-year overall survival (OS) than those not receiving HAART (74% versus 30%, P <0.001). The 2-year OS of HAART-responders was 88% compared with 19% in patients without HAART-response (P = 0.0002). By multivariate analysis patients without HAART had a 5.6-fold higher risk for 3-year mortality [HR 5.6, 95% confidence interval (CI) 2.20-14.26]. Three-year mortality was significantly higher in patients without complete remission (HR 4.40, CI 1.77-10.99), with stage III/IV HD (HR 4.64, CI 1.31-16.49) and with CD4 cells <200/microl (HR 2.69, CI 0.99-7.33). CONCLUSIONS: Use of HAART significantly improved the overall survival in patients with HIV-HD.
Authors: Manfred Hensel; Armin Goetzenich; Thomas Lutz; Albrecht Stoehr; Arend Moll; Jürgen Rockstroh; Nicola Hanhoff; Hans Jäger; Franz Mosthaf Journal: Dtsch Arztebl Int Date: 2011-02-25 Impact factor: 5.594
Authors: Silvia Montoto; Kate Shaw; Jessica Okosun; Shreyans Gandhi; Paul Fields; Andrew Wilson; Milensu Shanyinde; Kate Cwynarski; Robert Marcus; Johannes de Vos; Anna Marie Young; Melinda Tenant-Flowers; Chloe Orkin; Margaret Johnson; Daniella Chilton; John G Gribben; Mark Bower Journal: J Clin Oncol Date: 2012-10-08 Impact factor: 44.544
Authors: Annie J Sasco; Antoine Jaquet; Emilie Boidin; Didier K Ekouevi; Fabian Thouillot; Thomas Lemabec; Marie-Anna Forstin; Philippe Renaudier; Paul N'dom; Denis Malvy; François Dabis Journal: PLoS One Date: 2010-01-11 Impact factor: 3.240
Authors: Daria Gotti; Elena Raffetti; Laura Albini; Laura Sighinolfi; Franco Maggiolo; Elisa Di Filippo; Nicoletta Ladisa; Gioacchino Angarano; Giuseppe Lapadula; Angelo Pan; Anna Degli Esposti; Massimiliano Fabbiani; Emanuele Focà; Alfredo Scalzini; Francesco Donato; Eugenia Quiros-Roldan Journal: PLoS One Date: 2014-04-23 Impact factor: 3.240
Authors: Francisco J Hernández-Walias; Esther Vázquez; Yolanda Pacheco; José M Rodríguez-Fernández; María J Pérez-Elías; Fernando Dronda; José L Casado; Ana Moreno; José M Hermida; Carmen Quereda; Asunción Hernando; Francisco Tejerina-Picado; Víctor Asensi; María J Galindo; Manuel Leal; Santiago Moreno; Alejandro Vallejo Journal: J Clin Med Date: 2020-03-11 Impact factor: 4.241